In our previous research, ROC analysis showed that the diagnostic power of galectin‐3 for pancreatic cancer greatly improved in combination with the conventional tumour markers CA19‐9 and CEA.15 This evidence concerns the gene CEACAM5 and familial pancreatic carcinoma.